Everolimus in poorly differentiated neuroendocrine carcinoma of unknown primary: A case report

Malignancies with unknown primaries contribute to a small yet significant percentage of overall tumors. Neuroendocrine carcinomas, a rare disease with a poor prognosis, have been known to present as an unknown primary. Treatment consists of cytotoxic chemotherapy but given the latter’s high toxicity...

Descripción completa

Detalles Bibliográficos
Autores principales: Bou Zerdan, Maroun, Hamouche, Ramzi, Bouferraa, Youssef, Chouairy, Camil, Gholam, Dany
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247284/
https://www.ncbi.nlm.nih.gov/pubmed/35783669
http://dx.doi.org/10.1177/2050313X221106987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247284/
https://www.ncbi.nlm.nih.gov/pubmed/35783669
http://dx.doi.org/10.1177/2050313X221106987

Ejemplares similares